LAUSR

In people with type 1 or 2 diabetes, cardiovascular autonomic neuropathy (CAN) is associated with the development of atherosclerotic cardiovascular disease (CVD) and with a high risk of lethal arrhythmias and sudden death. In the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial, which included people with type 2 diabetes, participants with CAN at baseline were 1.55 to 2.14 times more likely to die than participants without CAN, and the presence of orthostatic hypotension (OH) at baseline was also associated with an increased risk of total death (hazard ratio, 1.61) and death or hospitalization due to heart failure (hazard ratio, 1.85).